Crinetics Pharmaceuticals, Inc. 8-K

What Happened
Crinetics Pharmaceuticals (CRNX) filed an 8-K on January 13, 2026 reiterating preliminary, unaudited financial and operating results for the quarter ended December 31, 2025. The company said it expects to report net product revenue from PALSONIFY™ (paltusotine) of over $5.0 million for Q4 2025. Crinetics’ audited financial statements for the full year 2025 are not yet available, and the estimate is subject to completion of closing procedures and management review.

Key Details

• Crinetics expects PALSONIFY net product revenue of > $5.0 million for the three months ended Dec 31, 2025 (preliminary, unaudited).
• The 8-K was filed Jan 13, 2026; audited 2025 statements are pending and results may change materially.
• CEO Scott Struthers presented a company update at the J.P. Morgan Healthcare Conference on Jan 13, 2026 (9:45 a.m. PT); slides are included as Exhibit 99.1 and a live webcast was available.
• The disclosure includes standard forward-looking statement caution: projections and plans are subject to risks and uncertainties described in Crinetics’ SEC filings.

Why It Matters
This filing gives the first public, preliminary revenue signal for PALSONIFY’s commercial launch and provides investors a rough Q4 revenue benchmark. Because the figure is unaudited and management cautions it may change, investors should treat it as an early estimate and await the company’s finalized, audited 2025 financial statements for a confirmed view of quarterly and full-year performance. The CEO’s J.P. Morgan presentation may also contain operational and development updates that could affect near-term expectations.